CA2971071C - Utilisation de la milrinone et derives connexes dans le traitement d'une insuffisance cardiaque avec fraction d'ejection preservee (hfpef) - Google Patents

Utilisation de la milrinone et derives connexes dans le traitement d'une insuffisance cardiaque avec fraction d'ejection preservee (hfpef)

Info

Publication number
CA2971071C
CA2971071C CA2971071A CA2971071A CA2971071C CA 2971071 C CA2971071 C CA 2971071C CA 2971071 A CA2971071 A CA 2971071A CA 2971071 A CA2971071 A CA 2971071A CA 2971071 C CA2971071 C CA 2971071C
Authority
CA
Canada
Prior art keywords
use according
coating
milrinone
pharmaceutically acceptable
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2971071A
Other languages
English (en)
Other versions
CA2971071A1 (fr
Inventor
David Kaye
Original Assignee
Baker IDI Heart and Diabetes Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker IDI Heart and Diabetes Institute filed Critical Baker IDI Heart and Diabetes Institute
Priority claimed from PCT/AU2015/050820 external-priority patent/WO2016101024A1/fr
Publication of CA2971071A1 publication Critical patent/CA2971071A1/fr
Application granted granted Critical
Publication of CA2971071C publication Critical patent/CA2971071C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne l’utilisation d’une formulation pour l’administration prolongée de l,2-dihydro-3-cyano-6-méthyl-5-(4-pyridinyle)-2(1H)-pyridinone (milrinone) ou d’un sel acceptable sur le plan pharmaceutique connexe pour le traitement d’un patient souffrant d’une insuffisance cardiaque à fraction d’éjection préservée (ICFEP).
CA2971071A 2014-12-22 2015-12-21 Utilisation de la milrinone et derives connexes dans le traitement d'une insuffisance cardiaque avec fraction d'ejection preservee (hfpef) Active CA2971071C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014905194 2014-12-22
AU2014905194A AU2014905194A0 (en) 2014-12-22 Method of Treatment
PCT/AU2015/050820 WO2016101024A1 (fr) 2014-12-22 2015-12-21 Procédé de traitement

Publications (2)

Publication Number Publication Date
CA2971071A1 CA2971071A1 (fr) 2016-06-30
CA2971071C true CA2971071C (fr) 2026-03-03

Family

ID=

Similar Documents

Publication Publication Date Title
US11291660B2 (en) Method of treating heart failure with preserved ejection fraction by administering milrinone
US10098845B2 (en) Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US11331274B2 (en) Milrinone controlled-release formulation
JP4457003B2 (ja) 放出制御医薬組成物
JP4439499B2 (ja) アムロジピン含有粒子およびそれからなる口腔内崩壊錠
CA2971071C (fr) Utilisation de la milrinone et derives connexes dans le traitement d'une insuffisance cardiaque avec fraction d'ejection preservee (hfpef)
EP4591722A1 (fr) Composition à libération prolongée de saccharide et son procédé de préparation
JP5241681B2 (ja) アムロジピン含有粒子およびそれからなる口腔内崩壊錠
NZ732954B2 (en) Method of Treating Heart Failure with Preserved Ejection Fraction with 5-(Pyridinyl)-2(1H)-pyridinone Compounds
EP1784161B1 (fr) Formulation à libération contrôlée comprenant de l'hydrochlorure de tamsulosine
US20250195417A1 (en) Additive composition for orally disintegrating tablet
NZ718686B2 (en) Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof